-
公开(公告)号：US20050186216A1
公开(公告)日：2005-08-25
申请号：US11088570
申请日：2005-03-23
IPC分类号： C07K16/28 , C07K16/46 , A61K39/395
CPC分类号： C07K16/46 , A61K2039/505 , C07K16/2809 , C07K16/2818 , C07K16/2878 , C07K16/2896 , C07K16/462 , C07K2317/22 , C07K2317/24 , C07K2317/53 , C07K2317/622 , C07K2317/64 , C07K2317/732 , C07K2317/734 , C07K2319/00 , C07K2319/30
摘要： The invention relates to novel binding domain-immunoglobulin fusion proteins that feature a binding domain for a cognate structure such as an antigen, a counterreceptor or the like, a hinge region polypeptide having either zero or one cysteine residue, and immunoglobulin CH2 and CH3 domains, and that are capable of ADCC and/or CDC while occurring predominantly as monomeric polypeptides. The fusion proteins can be recombinantly produced at high expression levels. Also provided are related compositions and methods, including immunotherapeutic applications.
摘要翻译： 本发明涉及新颖的结合域 - 免疫球蛋白融合蛋白，其特征在于同源结构如结合抗原，反式受体等的结合结构域，具有零个或一个半胱氨酸残基的铰链区多肽和免疫球蛋白CH2和CH3结构域， 并且其能够主要以单体多肽的形式存在于ADCC和/或CDC。 可以以高表达水平重组产生融合蛋白。 还提供了相关的组合物和方法，包括免疫治疗应用。
-
公开(公告)号：US20080031876A1
公开(公告)日：2008-02-07
申请号：US11725384
申请日：2007-03-19
申请人： Peter Linsley , Jeffrey Ledbetter , Nitin Damle , William Brady , Philip Wallace
发明人： Peter Linsley , Jeffrey Ledbetter , Nitin Damle , William Brady , Philip Wallace
IPC分类号： A61K39/395 , C07K14/435 , C07K14/705 , C07K14/715 , C07K16/18 , C07K16/28 , C12N15/12 , C12N15/62
CPC分类号： C07K16/247 , A61K38/00 , A61K2039/505 , C07K14/70521 , C07K14/7155 , C07K16/00 , C07K16/2818 , C07K16/2827 , C07K2317/34 , C07K2317/73 , C07K2319/00 , C07K2319/30 , Y10S514/885
摘要： The invention identifies the CTLA4 receptor as a ligand for the B7 antigen. The complete amino acid sequence encoding human CTLA4 receptor gene is provided. Methods are provided for expressing CTLA4 as an immunoglobulin fusion protein, for preparing hybrid CTLA4 fusion proteins, and for using the soluble fusion proteins, fragments and derivatives thereof, including monoclonal antibodies reactive with B7 and CTLA4, to regulate T cell interactions and immune responses mediated by such interactions.
摘要翻译： 本发明鉴定CTLA4受体作为B7抗原的配体。 提供编码人CTLA4受体基因的完整氨基酸序列。 提供用于表达CTLA4作为免疫球蛋白融合蛋白的方法，用于制备杂合CTLA4融合蛋白，并使用可溶性融合蛋白，其片段和衍生物，包括与B7和CTLA4反应的单克隆抗体调节T细胞相互作用和免疫应答介导 通过这种互动。
-
13.发明申请B-cell reduction using CD37-specific and CD20-specific binding molecules 审中-公开使用CD37特异性和CD20特异性结合分子的B细胞减少公开(公告)号：US20070059306A1
公开(公告)日：2007-03-15
申请号：US11493132
申请日：2006-07-25
申请人： Laura Grosmaire , Martha Hayden-Ledbetter , Jeffrey Ledbetter , Peter Thompson , Sandy Simon , William Brady
发明人： Laura Grosmaire , Martha Hayden-Ledbetter , Jeffrey Ledbetter , Peter Thompson , Sandy Simon , William Brady
IPC分类号： A61K39/395
CPC分类号： A61K39/3955 , A61K39/39558 , A61K45/06 , A61K2039/505 , A61K2039/507 , A61K2039/545 , C07K16/2887 , C07K16/2896 , C07K16/30 , C07K16/3061 , C07K2317/24 , C07K2317/52 , C07K2317/53 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/622 , C07K2317/72 , C07K2317/73 , C07K2317/732 , C07K2317/734 , C07K2317/75 , C07K2317/76 , A61K2300/00
摘要： The present invention generally provides methods for B-cell reduction in an individual using CD37-specific binding molecules. In particular, the invention provides methods for B-cell reduction using CD37-specific binding molecules alone, or a combination of CD37-specific binding molecules and CD20-specific binding molecules, in some instances a synergistic combination. The invention further provides materials and methods for treatment of diseases involving aberrant B-cell activity. In addition, the invention provides humanized CD37-specific binding molecules.
摘要翻译： 本发明通常提供使用CD37特异性结合分子的个体中B细胞减少的方法。 特别地，本发明提供了使用单独的CD37-特异性结合分子或CD37-特异性结合分子和CD20-特异性结合分子的组合（在某些情况下是协同组合）的B细胞减少的方法。 本发明还提供了用于治疗涉及异常B细胞活性的疾病的材料和方法。 此外，本发明提供了人源化的CD37特异性结合分子。
-
公开(公告)号：US20050238646A1
公开(公告)日：2005-10-27
申请号：US11089368
申请日：2005-03-23
IPC分类号： C07K16/28 , C07K16/46 , A61K39/395
CPC分类号： C07K16/46 , A61K2039/505 , C07K16/2809 , C07K16/2818 , C07K16/2878 , C07K16/2896 , C07K16/462 , C07K2317/22 , C07K2317/24 , C07K2317/53 , C07K2317/622 , C07K2317/64 , C07K2317/732 , C07K2317/734 , C07K2319/00 , C07K2319/30
摘要： The invention relates to novel binding domain-immunoglobulin fusion proteins that feature a binding domain for a cognate structure such as an antigen, a counterreceptor or the like, a hinge region polypeptide having either zero or one cysteine residue, and immunoglobulin CH2 and CH3 domains, and that are capable of ADCC and/or CDC while occurring predominantly as monomeric polypeptides. The fusion proteins can be recombinantly produced at high expression levels. Also provided are related compositions and methods, including immunotherapeutic applications.
-
公开(公告)号：US20050202012A1
公开(公告)日：2005-09-15
申请号：US11088737
申请日：2005-03-23
IPC分类号： C07K16/28 , C07K16/46 , A61K39/395
CPC分类号： C07K16/46 , A61K2039/505 , C07K16/2809 , C07K16/2818 , C07K16/2878 , C07K16/2896 , C07K16/462 , C07K2317/22 , C07K2317/24 , C07K2317/53 , C07K2317/622 , C07K2317/64 , C07K2317/732 , C07K2317/734 , C07K2319/00 , C07K2319/30
摘要： The invention relates to novel binding domain-immunoglobulin fusion proteins that feature a binding domain for a cognate structure such as an antigen, a counterreceptor or the like, a hinge region polypeptide having either zero or one cysteine residue, and immunoglobulin CH2 and CH3 domains, and that are capable of ADCC and/or CDC while occurring predominantly as monomeric polypeptides. The fusion proteins can be recombinantly produced at high expression levels. Also provided are related compositions and methods, including immunotherapeutic applications.
摘要翻译： 本发明涉及新颖的结合域 - 免疫球蛋白融合蛋白，其特征在于同源结构如结合抗原，反式受体等的结合结构域，具有零个或一个半胱氨酸残基的铰链区多肽和免疫球蛋白CH2和CH3结构域， 并且其能够主要以单体多肽的形式存在于ADCC和/或CDC。 可以以高表达水平重组产生融合蛋白。 还提供了相关的组合物和方法，包括免疫治疗应用。
-
公开(公告)号：US20050180970A1
公开(公告)日：2005-08-18
申请号：US11089190
申请日：2005-03-23
IPC分类号： C07K16/28 , C07K16/46 , A61K39/395 , C12P21/04
CPC分类号： C07K16/46 , A61K2039/505 , C07K16/2809 , C07K16/2818 , C07K16/2878 , C07K16/2896 , C07K16/462 , C07K2317/22 , C07K2317/24 , C07K2317/53 , C07K2317/622 , C07K2317/64 , C07K2317/732 , C07K2317/734 , C07K2319/00 , C07K2319/30
摘要： The invention relates to novel binding domain-immunoglobulin fusion proteins that feature a binding domain for a cognate structure such as an antigen, a counterreceptor or the like, a hinge region polypeptide having either zero or one cysteine residue, and immunoglobulin CH2 and CH3 domains, and that are capable of ADCC and/or CDC while occurring predominantly as monomeric polypeptides. The fusion proteins can be recombinantly produced at high expression levels. Also provided are related compositions and methods, including immunotherapeutic applications.
-
公开(公告)号：US20050261478A1
公开(公告)日：2005-11-24
申请号：US11128440
申请日：2005-05-12
申请人： Jeffrey Ledbetter , Martha Hayden Ledbetter , William Brady , Laura Grosmaire , Che-Leung Law , Raj Dua
发明人： Jeffrey Ledbetter , Martha Hayden Ledbetter , William Brady , Laura Grosmaire , Che-Leung Law , Raj Dua
IPC分类号： C12N15/09 , A61K38/00 , A61P37/02 , C07K14/47 , C07K14/705 , C07K14/725 , C07K16/00 , C07K16/18 , C07K16/28 , C07K19/00 , C12N5/06 , C12N5/10
CPC分类号： C07K16/00 , C07K16/2806 , C07K16/2809 , C07K16/2818 , C07K16/2878 , C07K2317/22 , C07K2317/24 , C07K2317/34 , C07K2317/56 , C07K2317/565 , C07K2317/74 , C07K2319/00
摘要： The present invention relates to regulation of lymphocyte activation. In particular, it relates to compositions and methods for regulating lymphocyte activation by selectively binding multiple cell surface antigens expressed by the same lymphocyte.
摘要翻译： 本发明涉及淋巴细胞活化的调节。 特别地，本发明涉及通过选择性结合由相同淋巴细胞表达的多种细胞表面抗原来调节淋巴细胞活化的组合物和方法。
-
公开(公告)号：US20050202534A1
公开(公告)日：2005-09-15
申请号：US11089367
申请日：2005-03-23
CPC分类号： C07K16/46 , A61K2039/505 , C07K16/2809 , C07K16/2818 , C07K16/2878 , C07K16/2896 , C07K16/462 , C07K2317/22 , C07K2317/24 , C07K2317/53 , C07K2317/622 , C07K2317/64 , C07K2317/732 , C07K2317/734 , C07K2319/00 , C07K2319/30
摘要： The invention relates to novel binding domain-immunoglobulin fusion proteins that feature a binding domain for a cognate structure such as an antigen, a counterreceptor or the like, a hinge region polypeptide having either zero or one cysteine residue, and immunoglobulin CH2 and CH3 domains, and that are capable of ADCC and/or CDC while occurring predominantly as monomeric polypeptides. The fusion proteins can be recombinantly produced at high expression levels. Also provided are related compositions and methods, including immunotherapeutic applications.
-
公开(公告)号：US20050169919A1
公开(公告)日：2005-08-04
申请号：US10461000
申请日：2003-06-13
申请人： Peter Linsley , Jeffrey Ledbetter , Nitin Damle , William Brady
发明人： Peter Linsley , Jeffrey Ledbetter , Nitin Damle , William Brady
IPC分类号： A61K38/00 , C07K14/705 , C07K14/715 , C07K16/00 , C07K16/28 , A61K39/395 , C07K14/74
CPC分类号： C07K16/247 , A61K38/00 , A61K2039/505 , C07K14/70521 , C07K14/7155 , C07K16/00 , C07K16/2818 , C07K16/2827 , C07K2317/34 , C07K2317/73 , C07K2319/00 , C07K2319/30 , Y10S514/885
摘要： The invention identifies the CTLA4 receptor as a ligand for the B7 antigen. The complete amino acid sequence encoding human CTLA4 receptor gene is provided. Methods are provided for expressing CTLA4 as an immunoglobulin fusion protein, for preparing hybrid CTLA4 fusion proteins, and for using the soluble fusion proteins, fragments and derivatives thereof, including monoclonal antibodies reactive with B7 and CTLA4, to regulate T cell interactions and immune responses mediated by such interactions.
摘要翻译： 本发明鉴定CTLA4受体作为B7抗原的配体。 提供编码人CTLA4受体基因的完整氨基酸序列。 提供用于表达CTLA4作为免疫球蛋白融合蛋白的方法，用于制备杂合CTLA4融合蛋白，并使用可溶性融合蛋白，其片段和衍生物，包括与B7和CTLA4反应的单克隆抗体调节T细胞相互作用和免疫应答介导 通过这种互动。
-
20.发明授权Methods for prolonging the expression of a heterologous gene of interest using soluble CTLA4 molecules and an antiCD40 ligand 失效使用可溶性CTLA4分子和抗CD40配体延长感兴趣的异源基因表达的方法
公开(公告)号：US5993800A
公开(公告)日：1999-11-30
申请号：US474210
申请日：1995-06-06
申请人： Peter S. Linsley , Mark A. Kay , Christopher B. Wilson , Jeffrey Ledbetter , Alejandro A. Aruffo , Diane L. Hollenbaugh
发明人： Peter S. Linsley , Mark A. Kay , Christopher B. Wilson , Jeffrey Ledbetter , Alejandro A. Aruffo , Diane L. Hollenbaugh
IPC分类号： A61K38/00 , A61K48/00 , C07K14/705 , C12N15/86 , C12N15/861
CPC分类号： C12N15/86 , A61K48/00 , C07K14/70521 , A61K38/00 , C07K2319/00 , C12N2710/10343 , C12N2810/859 , C12N2840/203
摘要： The invention provides a method for enhancing the expression of a gene of interest by a cell, the cell (a) comprises a recombinant nucleic acid sequence encoding and (b) is capable of expressing the gene of interest, the method comprising contacting the cell with an amount of a soluble CTLA4 molecule effective to enhance the expression of the gene of interest by the cell.
摘要翻译： 本发明提供了一种用于增强细胞表达目的基因的方法，所述细胞（a）包含编码和（b）能够表达目的基因的重组核酸序列，所述方法包括使细胞与 一定量的有效增强细胞所关注的基因表达的可溶性CTLA4分子。
-
-
-
-
-
-
-
-
-
搜索结果
20 条记录 (耗时 0.032 秒)
